Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development

Huiling Li, Sumana R. Chintalapudi, Monica M. Jablonski

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Introduction: Age-related macular degeneration (AMD) is the leading cause of vision loss among the elderly. Atrophic AMD, including early, intermediate and geographic atrophy (GA), accounts for ~90% of all cases. It is a multifactorial degeneration characterized by chronic inflammation, oxidative stress and aging components. Although no FDA-approved treatment yet exists for the late stage of atrophic AMD, multiple pathological mechanisms are partially known and several promising therapies are in various stages of development. Areas covered: Underlying mechanisms that define atrophic AMD will help provide novel therapeutic targets that will address this largely unmet clinical need. The purpose of this paper is to review current promising drugs that are being evaluated in clinical trials. Because no pharmacological treatments are currently available for late stage of atrophic AMD, any new therapy would have extensive market potential. Expert opinion: The number of AMD patients is predicted to increase to ~30 million worldwide by 2020. In response to this enormous unmet clinical need, new promising therapies are being developed and evaluated in clinical trials. We propose that the assessment of novel interventions will also need to consider the genotypes of participants, as the benefit may be determined by polymorphisms in an individual’s genetic background.

Original languageEnglish (US)
Pages (from-to)1103-1114
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number10
DOIs
StatePublished - Oct 3 2017

Fingerprint

Macular Degeneration
Drug Therapy
Therapeutics
Geographic Atrophy
Clinical Trials
Expert Testimony
Oxidative Stress
Genotype
Pharmacology
Inflammation
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration : phase I to phase III clinical development. / Li, Huiling; Chintalapudi, Sumana R.; Jablonski, Monica M.

In: Expert Opinion on Investigational Drugs, Vol. 26, No. 10, 03.10.2017, p. 1103-1114.

Research output: Contribution to journalReview article

@article{27a5afbc0c0547d9ac680ff48061fca6,
title = "Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development",
abstract = "Introduction: Age-related macular degeneration (AMD) is the leading cause of vision loss among the elderly. Atrophic AMD, including early, intermediate and geographic atrophy (GA), accounts for ~90{\%} of all cases. It is a multifactorial degeneration characterized by chronic inflammation, oxidative stress and aging components. Although no FDA-approved treatment yet exists for the late stage of atrophic AMD, multiple pathological mechanisms are partially known and several promising therapies are in various stages of development. Areas covered: Underlying mechanisms that define atrophic AMD will help provide novel therapeutic targets that will address this largely unmet clinical need. The purpose of this paper is to review current promising drugs that are being evaluated in clinical trials. Because no pharmacological treatments are currently available for late stage of atrophic AMD, any new therapy would have extensive market potential. Expert opinion: The number of AMD patients is predicted to increase to ~30 million worldwide by 2020. In response to this enormous unmet clinical need, new promising therapies are being developed and evaluated in clinical trials. We propose that the assessment of novel interventions will also need to consider the genotypes of participants, as the benefit may be determined by polymorphisms in an individual’s genetic background.",
author = "Huiling Li and Chintalapudi, {Sumana R.} and Jablonski, {Monica M.}",
year = "2017",
month = "10",
day = "3",
doi = "10.1080/13543784.2017.1369042",
language = "English (US)",
volume = "26",
pages = "1103--1114",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration

T2 - phase I to phase III clinical development

AU - Li, Huiling

AU - Chintalapudi, Sumana R.

AU - Jablonski, Monica M.

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Introduction: Age-related macular degeneration (AMD) is the leading cause of vision loss among the elderly. Atrophic AMD, including early, intermediate and geographic atrophy (GA), accounts for ~90% of all cases. It is a multifactorial degeneration characterized by chronic inflammation, oxidative stress and aging components. Although no FDA-approved treatment yet exists for the late stage of atrophic AMD, multiple pathological mechanisms are partially known and several promising therapies are in various stages of development. Areas covered: Underlying mechanisms that define atrophic AMD will help provide novel therapeutic targets that will address this largely unmet clinical need. The purpose of this paper is to review current promising drugs that are being evaluated in clinical trials. Because no pharmacological treatments are currently available for late stage of atrophic AMD, any new therapy would have extensive market potential. Expert opinion: The number of AMD patients is predicted to increase to ~30 million worldwide by 2020. In response to this enormous unmet clinical need, new promising therapies are being developed and evaluated in clinical trials. We propose that the assessment of novel interventions will also need to consider the genotypes of participants, as the benefit may be determined by polymorphisms in an individual’s genetic background.

AB - Introduction: Age-related macular degeneration (AMD) is the leading cause of vision loss among the elderly. Atrophic AMD, including early, intermediate and geographic atrophy (GA), accounts for ~90% of all cases. It is a multifactorial degeneration characterized by chronic inflammation, oxidative stress and aging components. Although no FDA-approved treatment yet exists for the late stage of atrophic AMD, multiple pathological mechanisms are partially known and several promising therapies are in various stages of development. Areas covered: Underlying mechanisms that define atrophic AMD will help provide novel therapeutic targets that will address this largely unmet clinical need. The purpose of this paper is to review current promising drugs that are being evaluated in clinical trials. Because no pharmacological treatments are currently available for late stage of atrophic AMD, any new therapy would have extensive market potential. Expert opinion: The number of AMD patients is predicted to increase to ~30 million worldwide by 2020. In response to this enormous unmet clinical need, new promising therapies are being developed and evaluated in clinical trials. We propose that the assessment of novel interventions will also need to consider the genotypes of participants, as the benefit may be determined by polymorphisms in an individual’s genetic background.

UR - http://www.scopus.com/inward/record.url?scp=85029216994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029216994&partnerID=8YFLogxK

U2 - 10.1080/13543784.2017.1369042

DO - 10.1080/13543784.2017.1369042

M3 - Review article

C2 - 28816076

AN - SCOPUS:85029216994

VL - 26

SP - 1103

EP - 1114

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 10

ER -